Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene
How this was made
The 30-second read
Why it matters
Traders can update models for 2026 MRD revenue and operating expense expectations, and reassess financing and dilution risk following the completed convertible notes offering and OrbiMed repayment. The announced MRD/Immune Medicine separation adds a catalyst but with execution uncertainty.
Market read
The filing provides a concrete earnings-and-guidance update (Q2 print and raised MRD range) plus capital structure changes and a strategic separation plan, which together can drive repricing and positioning ahead of the call.
What to watch
Immune Medicine has no full-year revenue guidance and showed a 40% Q2 decline; separation execution timing and costs could also affect near-term margins and cash burn.
Background
This is an SEC Form 8-K with Exhibit 99.1 covering Adaptive Biotechnologies’ Q2 2026 results, updated 2026 MRD guidance, and financing plus leadership/strategic separation updates.
Ticker impact
Adaptive Biotechnologies reported Q2 2026 revenue of $71.6M, raised MRD guidance to $268M-$278M, and disclosed a $345M convertible notes offering.
Bias to upside on the guidance raise and separation optionality, with volatility around dilution/financing optics from the convertible notes.
The filing includes specific, time-sensitive datapoints: Q2 results, updated full-year MRD revenue range, and completion of a $345M zero-coupon convertible offering plus repayment of the OrbiMed Purchase Agreement.
Market effects
May modestly improve sentiment toward commercial-stage MRD/immune-diagnostics peers by signaling demand growth (clonoSEQ volume) and clearer capital structure.
Limited, as the disclosure is company-specific with no stated regional regulatory or procurement changes.
Low; no international regulatory or partnership terms beyond the referenced Genentech agreement impact on reported revenue.
Counterpoint
The raised MRD revenue guidance could be offset by continued high operating losses and dilution risk from the $345M convertible notes, keeping valuation sensitive to execution.
Key entities
- issuerAdaptive Biotechnologies Corporation
Commercial-stage biotech reporting Q2 2026 results, raising MRD guidance, completing $345M zero-coupon convertible notes, and announcing a planned business separation.
- business_segmentMRD business (Minimal Residual Disease)
Primary revenue driver, 92% of Q2 revenue, with clonoSEQ test volume growth and raised full-year guidance.
- business_segmentImmune Medicine business
Smaller segment with Q2 revenue decline and no full-year revenue guidance provided.
- financing_arrangementOrbiMed Purchase Agreement
Adaptive repaid under the agreement, described as part of increasing financial flexibility.
